Show simple item record

dc.contributor.authorRobbrecht, D
dc.contributor.authorEskens, F
dc.contributor.authorCalvo, E
dc.contributor.authorHe, XM
dc.contributor.authorHirai, H
dc.contributor.authorSoni, N
dc.contributor.authorCook, Natalie
dc.contributor.authorDowlati, A
dc.contributor.authorFasolo, A
dc.contributor.authorMoreno, V
dc.contributor.authorDe Bono, JS
dc.date.accessioned2019-11-19T16:01:08Z
dc.date.available2019-11-19T16:01:08Z
dc.date.issued2019en
dc.identifier.citationRobbrecht D, Eskens F, Calvo E, He X, Hirai H, Soni N, et al. First-in-human phase I and pharmacological study of TAS-119, a selective Aurora A (AurA) kinase inhibitor, in patients (pts) with advanced solid tumors. J Clin Oncol. 2019;37(15_suppl):3063-.en
dc.identifier.doi10.1200/JCO.2019.37.15_suppl.3063en
dc.identifier.urihttp://hdl.handle.net/10541/622466
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2019.37.15_suppl.3063en
dc.titleFirst-in-human phase I and pharmacological study of TAS-119, a selective Aurora A (AurA) kinase inhibitor, in patients (pts) with advanced solid tumorsen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentErasmus MC, Rotterdam, Netherlandsen
dc.identifier.journalJournal of Clinical Oncologyen


This item appears in the following Collection(s)

Show simple item record